The storage, preparation, and administration information in this Fact Sheet apply to the Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older, which is supplied in a multiple dose vial with a purple cap and MUST BE DILUTED before use. Pfizer-BioNTech COVID-19 Vaccine...
Click for Fact Sheets: For Consumers: EUA Fact sheet for Patients, Parents, and Caregivers For Healthcare Professionals: EUA Fact Sheet for HCPs INDICATION, AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION FOR COMIRNATY INDICATION COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine...
This cohort study describes the assessment and immunization of highly allergic individuals with the Pfizer-BioNTech COVID-19 vaccine, as well as the rate
This season’s vaccine is tailored to the SARS-CoV-2 XBB.1.5 sublineage and indicated as a single dose for most individuals 5 years of age and older Pre-clinical data show that the updated COVID-19 vaccine generates improved neutralizing antibody respons
Pfizer. (2017). Company Fact Sheet. Retrieved fromhttps://www.pfizer.com/about/leadership-and-structure/company-fact-sheet Pfizer. (2020, December 2). All COVID-19 Updates. Retrieved fromhttps://www.pfizer.com/science/coronavirus/updates ...
Learn more about 2024-2025 formula COVID-19 vaccines from BioNTech and Pfizer for individuals 6 months through 11 years of age and 12 years and older. See safety info.
decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of ELREXFIO; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and finan...
ration that circumstances exist justifying the authorization of emergency use ofthe medical product during the COVID-19 pandemic under Section 564(b)(1)of the FFDCA unless the declaration is terminated or authorization revoked sooner.Please see the EUA Fact Sheets and www.cvdvaccine-.This Form 10...
Create a free Seeking Alpha account to access breaking news and valuable research tools »Create Free AccountSeeking Alpha - Power to Investors Power to Investors Follow us Download app Account Account Login Manage My Portfolio Privacy Create Portfolio Portfolio Health Check...
Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’ COVID-19 vaccine T